Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Somedeb Ball, Michael T. Byrne, Melissa A Fischer, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Lokesh Patil, Christine J. Gu, Chris Leonardi, Katherine J. Walsh, Gregory Dan Ayers, Ashwin Kishtagari, Kateryna Fedorov, Markus D. Lacher, Joseph Wagner, Sanjay R Mohan, Michael R. Savona

Blood (2024) 144 (Supplement 1): 6012.

https://doi.org/10.1182/blood-2024-209403

Published: 2024

Journal Articles

Incidence of Cytopenia in Clonal Hematopoiesis of Indeterminate Potential

James Brogan, Ashwin Kishtagari, Robert W. Corty, Yash Pershad, Brian Sharber, Yaomin Xu, Alexander G. Bick

Blood (2024) 144 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2024-205713

Published: 2024

Journal Articles

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Haris Ali, Keri Maher, Ashwin Kishtagari, Sanjay R Mohan, Josef T. Prchal, Yi Chai, Christopher J. Walker, Trinayan Kashyap, Steve Kye, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 6676.

https://doi.org/10.1182/blood-2024-207778

Published: 2024

Journal Articles

Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications

Thomas J. Gracie, Yash Pershad, Cosmin Bejan, Alexander G. Bick, Brent Ferrell, Ashwin Kishtagari

Blood (2024) 144 (Supplement 1): 3607.

https://doi.org/10.1182/blood-2024-201083

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Simona Pagliuca, Carmelo Gurnari, Arda Durmaz, Ashwin Kishtagari, Zain Virk, Lukasz P. Gondek, Matthew Guo, Maria Bettinotti, Mark B Juckett, Qing Cao, Suresh Kumar Balasubramanian, Vikram Dhillon, Ben K. Tomlinson, Koen van Besien, Alice Aarnink, Marie Thérèse Rubio, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 927.

https://doi.org/10.1182/blood-2024-210565

Published: 2024

Journal Articles

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Kateryna Fedorov, Somedeb Ball, James E Denney, Alexis R Froenlich, Ashwin Kishtagari, Sanjay Mohan, Michael R. Savona, Emily F. Mason

Blood (2024) 144 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2024-194259

Published: 2024

Journal Articles

Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Ashwin Kishtagari, Zachary Copeland, Tracy Stewart, Julie Ryder, Carol Ragon, KiOsha Carlyle, Kerri Harrison, Clayton Allen, Ryan Yates, Andrew Benefield, Nina Logan, Brion Randolph, Salil Goorha, Lammers Philip, Alexander G. Bick, Michael R. Savona

Blood (2024) 144 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2024-206418

Published: 2024

Journal Articles

Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Alyssa C. Parker, Joseph C. Van Amburg, Tianzi Zhang, Diane C. Saunders, Thomas J. Gracie, Pawan Bhat, J. Brett Heimlich, John W. Hickey, Emily F. Mason, Ashwin Kishtagari, P. Brent Ferrell, Jr., Alexander G. Bick

Blood (2024) 144 (Supplement 1): 4577.

https://doi.org/10.1182/blood-2024-210307

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Jeremy V. DiGennaro, George Concepcion, Najla H. Al Ali, Onyee Chan, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, David Sallman, Ashwin Kishtagari, Pankit Vachhani, John O. Mascarenhas, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2024-202579

Published: 2024

Journal Articles

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Carmelo Gurnari, Hussein Awada, Simona Pagliuca, Danai Dima, Fauzia Ullah, Naomi Kawashima, Yasuo Kubota, Ceylan Colak, Valeria Visconte, Bhumika J. Patel, Vikram Dhillon, Naimisha Marneni, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Taha Bat, Jaroslaw P. Maciejewski

Blood (2024) 144 (2): 145–155.

https://doi.org/10.1182/blood.2024023988

Published: 2024

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Pankit Vachhani, Abdulraheem Yacoub, Elie Traer, Lina Benajiba, Francesco Passamonti, Ashwin Kishtagari, Mojtaba Akhtari, James McCloskey, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas

Blood (2023) 142 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2023-178725

Published: 2023

Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2023-178090

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Incidence of Cytopenia in Clonal Hematopoiesis of Indeterminate Potential

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients

Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only